112 related articles for article (PubMed ID: 8691988)
21. Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes.
Masubuchi Y; Kagimoto N; Narimatsu S; Fujita S; Suzuki T
Drug Metab Dispos; 1993; 21(6):1012-6. PubMed ID: 7905378
[TBL] [Abstract][Full Text] [Related]
22. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
Prueksaritanont T; Dwyer LM; Cribb AE
Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
[TBL] [Abstract][Full Text] [Related]
23. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
Meier PJ; Mueller HK; Dick B; Meyer UA
Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
[TBL] [Abstract][Full Text] [Related]
24. Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes.
Cooke BR; Bligh SW; Cybulski ZR; Ioannides C; Hall M
Drug Metab Dispos; 2012 Jan; 40(1):70-5. PubMed ID: 21976620
[TBL] [Abstract][Full Text] [Related]
25. Identification of the cytochrome P-450 isozymes responsible for testosterone oxidation in rat lung, kidney, and testis: evidence that cytochrome P-450a (P450IIA1) is the physiologically important testosterone 7 alpha-hydroxylase in rat testis.
Sonderfan AJ; Arlotto MP; Parkinson A
Endocrinology; 1989 Aug; 125(2):857-66. PubMed ID: 2752981
[TBL] [Abstract][Full Text] [Related]
26. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
Inaba T; Nakano M; Otton SV; Mahon WA; Kalow W
Can J Physiol Pharmacol; 1984 Jul; 62(7):860-2. PubMed ID: 6498616
[TBL] [Abstract][Full Text] [Related]
27. Expression and characterization of dog CYP2D15 using baculovirus expression system.
Tasaki T; Nakamura A; Itoh S; Ohashi K; Yamamoto Y; Masuda M; Iwata H; Kazusaka A; Kamataki T; Fujita S
J Biochem; 1998 Jan; 123(1):162-8. PubMed ID: 9504424
[TBL] [Abstract][Full Text] [Related]
28. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.
Jaruratanasirikul S; Cooper AD; Blaschke TF
Drug Metab Dispos; 1992; 20(3):379-82. PubMed ID: 1355711
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.
Distlerath LM; Guengerich FP
Proc Natl Acad Sci U S A; 1984 Dec; 81(23):7348-52. PubMed ID: 6594694
[TBL] [Abstract][Full Text] [Related]
31. Is cytochrome P450 CYP2D activity present in pig liver?
Skaanild MT; Friis C
Pharmacol Toxicol; 2002 Oct; 91(4):198-203. PubMed ID: 12530471
[TBL] [Abstract][Full Text] [Related]
32. Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9-mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine.
Hietanen E; Malaveille C; Camus AM; Béréziat JC; Brun G; Castegnaro M; Michelon J; Idle JR; Bartsch H
Drug Metab Dispos; 1986; 14(1):118-26. PubMed ID: 2868854
[TBL] [Abstract][Full Text] [Related]
33. Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol.
Masubuchi Y; Fujita S; Chiba M; Kagimoto N; Umeda S; Suzuki T
Biochem Pharmacol; 1991 Mar 15-Apr 1; 41(6-7):861-5. PubMed ID: 2009081
[TBL] [Abstract][Full Text] [Related]
34. Interaction of plasma proteins with cytochromes P450 mediated metabolic reactions: inhibition by human serum albumin and alpha-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat.
Ishii M; Xu BQ; Ding LR; Fischer NE; Inaba T
Toxicol Lett; 2001 Mar; 119(3):219-25. PubMed ID: 11246175
[TBL] [Abstract][Full Text] [Related]
35. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.
Wolff T; Distlerath LM; Worthington MT; Groopman JD; Hammons GJ; Kadlubar FF; Prough RA; Martin MV; Guengerich FP
Cancer Res; 1985 May; 45(5):2116-22. PubMed ID: 3921236
[TBL] [Abstract][Full Text] [Related]
36. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity.
Wan J; Imaoka S; Chow T; Hiroi T; Yabusaki Y; Funae Y
Arch Biochem Biophys; 1997 Dec; 348(2):383-90. PubMed ID: 9434752
[TBL] [Abstract][Full Text] [Related]
37. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
38. Oxidative metabolism of cinnarizine in rat liver microsomes.
Kariya S; Isozaki S; Narimatsu S; Suzuki T
Biochem Pharmacol; 1992 Oct; 44(7):1471-4. PubMed ID: 1417969
[TBL] [Abstract][Full Text] [Related]
39. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
Venhorst J; ter Laak AM; Commandeur JN; Funae Y; Hiroi T; Vermeulen NP
J Med Chem; 2003 Jan; 46(1):74-86. PubMed ID: 12502361
[TBL] [Abstract][Full Text] [Related]
40. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
